Physician profile
Ashwin Chandra
NPI 1700445608
$1,182.44
in general payments reported to CMS, 2019-2025
16 companies · $155 in 2025
The $155 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.52 · 2020: $242 · 2021: $103 · 2022: $546 · 2024: $124 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $278.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $247.78 | 2022-2025 | |
| Novo Nordisk INC | $149.44 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $137.67 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $125.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.00 | 2020 | |
| Janssen Pharmaceuticals, INC | $114.99 | 2020 | |
| Mimedx Group, INC. | $93.48 | 2024 | |
| Glaxosmithkline, LLC. | $37.98 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $31.84 | 2025 | |
| Kyowa Kirin, INC. | $24.48 | 2021 | |
| Pfizer INC. | $23.68 | 2019-2021 | |
| Daiichi Sankyo INC. | $21.20 | 2022 | |
| Axonics, INC. | $19.26 | 2024 | Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.19 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $10.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Chandra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.